Ann: Opthea Announces Plans for Potential US listing and IPO, page-2

Well this was not an option that had crossed my mind for funding Phase 3...

ASX and Media Release
24 August 2020
Opthea Announces Plans to Conduct Registered Public Offering and
Listing in the United States
Melbourne, Australia; 24 August 2020 – Opthea Limited (ASX:OPT) today announces that it has
confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and
Exchange Commission (the “SEC”) relating to a potential initial public offering of American Depositary
Shares (“ADSs”) in the U.S. representing Opthea’s ordinary shares, which will remain listed on the
Australian Securities Exchange, and concurrent listing of the ADSs on the Nasdaq Stock Market
(“Nasdaq”). Any offering and listing of ADSs on Nasdaq would be intended to support Opthea’s
product development activities, including its previously announced Phase 3 trials of OPT-302 for the
treatment of wet AMD. The number of ADSs that may be offered, the number of underlying ordinary
shares that may be issued, the price for such instruments and the timing of the offering have not yet
been determined. Any offering is expected to commence after the SEC completes its review process,
subject to market conditions, investor demand and shareholder approval. No final decision has been
made in respect of any additional listing and there can be no assurance as to the occurrence, timing
and/or completion of such a listing.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any
securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in
accordance with the registration requirements of the Securities Act of 1933, as amended (“Securities
Act”). This announcement is being issued in accordance with Rule 135 under the Securities Act.